Literature DB >> 26407791

Ketamine for depression: evidence, challenges and promise.

Carlos A Zarate1, Mark J Niciu1.   

Abstract

Entities:  

Year:  2015        PMID： 26407791      PMCID： PMC4592658          DOI： 10.1002/wps.20269

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  29 in total

1.  Clinical predictors of ketamine response in treatment-resistant major depression.

Authors:  Mark J Niciu; David A Luckenbaugh; Dawn F Ionescu; Sara Guevara; Rodrigo Machado-Vieira; Erica M Richards; Nancy E Brutsche; Neal M Nolan; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2014-05       Impact factor: 4.384

2.  Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors:  B Moghaddam; B Adams; A Verma; D Daly
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

3.  Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice.

Authors:  E Beurel; L Song; R S Jope
Journal:  Mol Psychiatry       Date:  2011-04-19       Impact factor: 15.992

4.  Serial infusions of low-dose ketamine for major depression.

Authors:  Keith G Rasmussen; Timothy W Lineberry; Christine W Galardy; Simon Kung; Maria I Lapid; Brian A Palmer; Matthew J Ritter; Kathryn M Schak; Christopher L Sola; Allison J Hanson; Mark A Frye
Journal:  J Psychopharmacol       Date:  2013-02-20       Impact factor: 4.153

5.  Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Authors:  James W Murrough; Andrew M Perez; Sarah Pillemer; Jessica Stern; Michael K Parides; Marije aan het Rot; Katherine A Collins; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu
Journal:  Biol Psychiatry       Date:  2012-07-27       Impact factor: 13.382

6.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

7.  Pilot dose-response trial of i.v. ketamine in treatment-resistant depression.

Authors:  Rosalyn Lai; Natalie Katalinic; Paul Glue; Andrew A Somogyi; Philip B Mitchell; John Leyden; Simon Harper; Colleen K Loo
Journal:  World J Biol Psychiatry       Date:  2014-06-09       Impact factor: 4.132

8.  Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression.

Authors:  Mark J Niciu; David A Luckenbaugh; Dawn F Ionescu; Daniel C Mathews; Erica M Richards; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2013-05-28       Impact factor: 13.382

9.  Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.

Authors:  Rebecca B Price; Dan V Iosifescu; James W Murrough; Lee C Chang; Rayan K Al Jurdi; Syed Z Iqbal; Laili Soleimani; Dennis S Charney; Alexandra L Foulkes; Sanjay J Mathew
Journal:  Depress Anxiety       Date:  2014-03-25       Impact factor: 6.505

10.  Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.

Authors:  Peter R Diamond; Andrew D Farmery; Stephanie Atkinson; Jag Haldar; Nicola Williams; Phil J Cowen; John R Geddes; Rupert McShane
Journal:  J Psychopharmacol       Date:  2014-04-03       Impact factor: 4.153
View more
  10 in total

1.  Comparative Transcriptomic Analysis of the Effects of Antidepressant Drugs in Stress-Susceptible Mice.

Authors:  Florian Duclot; Mohamed Kabbaj
Journal:  Biol Psychiatry       Date:  2017-02-15       Impact factor: 13.382

Review 2.  How do antidepressants work? New perspectives for refining future treatment approaches.

Authors:  Catherine J Harmer; Ronald S Duman; Philip J Cowen
Journal:  Lancet Psychiatry       Date:  2017-01-31       Impact factor: 27.083

3.  Ketamine and Ro 25-6981 Reverse Behavioral Abnormalities in Rats Subjected to Dietary Zinc Restriction.

Authors:  Bartłomiej Pochwat; Helena Domin; Anna Rafało-Ulińska; Bernadeta Szewczyk; Gabriel Nowak
Journal:  Int J Mol Sci       Date:  2020-07-06       Impact factor: 5.923

4.  Combination therapy with transcranial magnetic stimulation and ketamine for treatment-resistant depression: A long-term retrospective review of clinical use.

Authors:  Steven R D Best; Dan G Pavel; Natalie Haustrup
Journal:  Heliyon       Date:  2019-08-09

5.  Serum Levels of Tumor Necrosis Factor-α and Loudness Dependence of Auditory Evoked Potentials at Pretreatment and Posttreatment in Patients with Major Depressive Disorder.

Authors:  Bun-Hee Lee; Young-Min Park; Seung-Hwan Lee; Miseon Shim
Journal:  Brain Sci       Date:  2019-09-26

6.  Evaluation of Clinical Factors Associated with Adverse Drug Events in Patients Receiving Sub-Anesthetic Ketamine Infusions.

Authors:  Alexander D Stoker; David M Rosenfeld; Matthew R Buras; Jeremy M Alvord; Andrew W Gorlin
Journal:  J Pain Res       Date:  2019-12-23       Impact factor: 3.133

7.  Glutamic Acid Decarboxylase Concentration Changes in Response to Stress and Altered Availability of Glutamic Acid in Rabbit (Oryctolagus cuniculus) Brain Limbic Structures.

Authors:  Izabela Szpręgiel; Danuta Wrońska; Michał Kmiecik; Sylwia Pałka; Bogdan F Kania
Journal:  Animals (Basel)       Date:  2021-02-09       Impact factor: 2.752

Review 8.  Clinical research challenges posed by difficult-to-treat depression.

Authors:  A John Rush; Harold A Sackeim; Charles R Conway; Mark T Bunker; Steven D Hollon; Koen Demyttenaere; Allan H Young; Scott T Aaronson; Maxine Dibué; Michael E Thase; R Hamish McAllister-Williams
Journal:  Psychol Med       Date:  2022-01-07       Impact factor: 7.723

9.  Toward asleep DBS: cortico-basal ganglia spectral and coherence activity during interleaved propofol/ketamine sedation mimics NREM/REM sleep activity.

Authors:  Jing Guang; Halen Baker; Orilia Ben-Yishay Nizri; Shimon Firman; Uri Werner-Reiss; Vadim Kapuller; Zvi Israel; Hagai Bergman
Journal:  NPJ Parkinsons Dis       Date:  2021-08-02

10.  Effect of Ketamine on Limbic GABA and Glutamate: A Human In Vivo Multivoxel Magnetic Resonance Spectroscopy Study.

Authors:  Leo R Silberbauer; Benjamin Spurny; Patricia Handschuh; Manfred Klöbl; Petr Bednarik; Birgit Reiter; Vera Ritter; Patricia Trost; Melisande E Konadu; Marita Windpassinger; Thomas Stimpfl; Wolfgang Bogner; Rupert Lanzenberger; Marie Spies
Journal:  Front Psychiatry       Date:  2020-09-08       Impact factor: 4.157
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.